Moderna Inc's (NASDAQ: MRNA) coronavirus vaccine candidate mRNA-1273 gained another regulatory approval Tuesday.
Sixth Approval Secured: Cambridge, Massachusetts-based Moderna said Tuesday that Swissmedic, the Swiss Agency for Therapeutic Products, has authorized its vaccine in Switzerland.
The authorization was issued according to the "ordinary approvals" procedure, and was based on a rolling submission of data and the totality of scientific evidence shared by the company, Moderna said.
Moderna Strengthens Executive Team: The company announced the appointment of José M. Vega as its chief safety officer effective Jan. 11.
Related Link: The Week Ahead In Biotech (Jan 10-16): Expect Stocks To Move As J.P. Morgan Healthcare Conference Kicks Off The Swiss government has secured 7.5 million doses of mRNA-1273.